Journal
JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
Volume 15, Issue 7, Pages 756-763Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10286020.2013.800972
Keywords
rhein lysinate; SAMP8 mice; Alzheimer's disease; -amyloid; inflammation
Funding
- National Natural Science Foundation of China [81001439]
Ask authors/readers for more resources
The protective effect of rhein lysinate (RHL) on Alzheimer's disease (AD) was explored in senescence-accelerated mouse prone-8 (SAMP8) mice. SAMP8 mice without treatment were used as the AD-positive control, and senescence-accelerated-resistant mice were used as the AD-negative control. In this study, 4-month-old male SAMP8 mice were orally administered 25 and 50mg/kg RHL in drinking water for 6 months. The results of brain tissue enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, and Western blot were demonstrated that compared with SAMP8 group, -amyloid(1-40) and -amyloid(1-42) were reduced; the levels of tumor necrosis factor- and interleukin 6 of brain tissues were also significantly decreased; however, the level of sirtuin 1 (SIRT1) was increased in the RHL-treated group. Compared with SAMP8 group, the ROS levels and malondialdehyde levels were decreased; however, superoxide dismutase and glutathione peroxidase levels were increased in the brain tissues of SAMP8 25 and 50mg/kg RHL-treated groups. In conclusion, the reduction of A induced by RHL was related to the increase of SIRT1 and the inhibition of the inflammatory response and oxidative stress in SAMP8 mice. It might be a promising biological therapeutic drug for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available